Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study
Current Oncology · 01.08.2026 · 33 (8) · 460
DOI: 10.3390/curroncol33080460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 01.08.2026. Verfasst von Run Bao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophagogastric Junction, Immunotherapy, Claudins. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation, China Zhongguancun Precision Medicine Science and Technology Foundation, Suzhou Medical College of Soochow University - Qilu Medical Research Fund.
Abstract (Originalsprache)
This study aimed to characterize claudin 18.2 (CLDN18.2) expression in HER2-negative gastric or gastroesophageal junction cancer (GC/GEJC) and to evaluate whether CLDN18.2 status is associated with clinicopathological features and outcomes after first line chemoimmunotherapy. We retrospectively analyzed 189 patients with HER2-negative GC/GEJC treated at our institution from October 2019 to September 2024. CLDN18.2 expression was assessed by immunohistochemistry using two prespecified positivity thresholds: moderate to strong membranous staining (2+) in ≥40% or ≥75% of tumor cells. CLDN18.2 positivity was observed in 92/189 patients (48.7%) using the ≥40% threshold and 69/189 (36.5%) using the ≥75% threshold. PD L1 CPS ≥ 5 was less frequent in CLDN18.2 positive than in CLDN18.2 negative tumors at both thresholds (≥40%: 8.7% vs. 23.7%, p = 0.003; ≥75%: 8.7% vs. 20.8%, p = 0.019). Among 87 patients receiving first line chemoimmunotherapy, CLDN18.2 status was not associated with significant differences in objective response rate, progression free survival, or overall survival. CLDN18.2 positive tumors showed lower PD L1 expression, but CLDN18.2 status did not identify a subgroup with differential benefit from first line chemoimmunotherapy. These findings suggest that CLDN18.2 status does not appear to serve as a predictive biomarker for immune checkpoint inhibitor-based treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
- Department of Oncology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
- Department of Respiratory Medicine, Hangzhou First People's Hospital Tonglu Campus, Hangzhou 311500, China.
- Department of Oncology, Zhangjiagang First People's Hospital, Suzhou 215600, China.
- Department of Pathology, Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
- Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou 215006, China.
ORCID-Profile: Wangyang Pu
Förderung
- Wu Jieping Medical Foundation
- China Zhongguancun Precision Medicine Science and Technology Foundation
- Suzhou Medical College of Soochow University - Qilu Medical Research Fund
- The Second Affiliated Hospital of Soochow University Scientific Research Pre-Research Fund
- Suzhou Medical College of Soochow University—Qilu Medical Research Fund
Zitieren
APA
Bao, R., Qin, J., Zhang, R., Xu, Z., Liu, J., Shen, J., Zhang, S., Zhang, Y., Zhu, H., Huang, C., Lu, Y., Liu, T., & Pu, W. (2026). Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study. Current Oncology, 33(8), 460. https://doi.org/10.3390/curroncol33080460
Vancouver
Bao R, Qin J, Zhang R, Xu Z, Liu J, Shen J, et al. Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study. Current Oncology. 2026;33(8):460. doi:10.3390/curroncol33080460
BibTeX
@article{Bao2026,
author = {Bao, Run and Qin, Jing and Zhang, Rong and Xu, Zhuo and Liu, Jiahao and Shen, Jiaofeng and Zhang, Shunji and Zhang, Yusong and Zhu, Hong and Huang, Chunyan and Lu, Yan and Liu, Tianhua and Pu, Wangyang},
title = {Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {8},
pages = {460},
doi = {10.3390/curroncol33080460}
}
EUVIMED